MLH1 and gastric cancer: In the sporadic setting, more than 50% of MSI GCs contain an epigenetic hypermethylation of hMLH1 promoter, whereas mutations in hMLH1 and hMSH2 have been reported in 12–15% of this GC subgroup [32].